 D68 |
 |
Other coagulation defects  |
| |
| Excludes1 |
abnormal coagulation profile NOS (R79.1)
|
| Excludes2 |
coagulation defects complicating abortion or ectopic or molar pregnancy (O00-O07, O08.1)
coagulation defects complicating pregnancy, childbirth and the puerperium (O45.0, O46.0, O67.0, O72.3)
|
|
| |
| D68.0 |
|
Von Willebrand disease |
| |
| Excludes1 |
capillary fragility (hereditary) (D69.8)
factor VIII deficiency NOS (D66)
factor VIII deficiency with functional defect (D66)
|
|
| |
 D68.00 |
|
Von Willebrand disease, unspecified |
| | |
| D68.01 |
|
Von Willebrand disease, type 1 |
| |
| Partial quantitative deficiency of von Willebrand factor | | Type 1C von Willebrand disease |
|
| | |
| D68.02 |
|
Von Willebrand disease, type 2 |
| |
| Qualitative defects of von Willebrand factor |
|
| |
| D68.020 |
|
Von Willebrand disease, type 2A |
| |
| Qualitative defects of von Willebrand factor with decreased platelet adhesion and selective deficiency of high-molecular-weight multimers |
|
| | |
| D68.021 |
|
Von Willebrand disease, type 2B |
| |
| Qualitative defects of von Willebrand factor with high-molecular-weight von Willebrand factor loss | | Qualitative defects of von Willebrand factor with hyper-adhesive forms | | Qualitative defects of von Willebrand factor with increased affinity for platelet glycoprotein lb |
|
| | |
| D68.022 |
|
Von Willebrand disease, type 2M |
| |
| Qualitative defects of von Willebrand factor with defective platelet adhesion with a normal size distribution of von Willebrand factor multimers |
|
| | |
| D68.023 |
|
Von Willebrand disease, type 2N |
| |
| Qualitative defects of von Willebrand factor with defective von Willebrand factor to factor VIII binding | | Qualitative defects of von Willebrand factor with markedly decreased affinity for factor VIII |
|
| | |
| D68.029 |
|
Von Willebrand disease, type 2, unspecified |
| |
| Qualitative defect in von Willebrand factor function, with no further subtyping |
|
| | | |
| D68.03 |
|
Von Willebrand disease, type 3 |
| |
| (Near) complete absence of von Willebrand factor | | Total quantitative deficiency of von Willebrand factor |
|
| | |
| D68.04 |
|
Acquired von Willebrand disease |
| |
| Acquired von Willebrand syndrome |
|
| | |
| D68.09 |
|
Other von Willebrand disease |
| |
| Platelet-type von Willebrand disease | | Pseudo-von Willebrand disease |
| CodeAlso |
, if applicable, qualitative platelet defects (D69.1)
|
|
| |
| |
| D68.1 |
|
Hereditary factor XI deficiency |
| |
| Hemophilia C | | Plasma thromboplastin antecedent [PTA] deficiency | | Rosenthal's disease |
|
|
| |
| D68.2 |
|
Hereditary deficiency of other clotting factors |
| |
| AC globulin deficiency | | Congenital afibrinogenemia | | Deficiency of factor I [fibrinogen] | | Deficiency of factor II [prothrombin] | | Deficiency of factor V [labile] | | Deficiency of factor VII [stable] | | Deficiency of factor X [Stuart-Prower] | | Deficiency of factor XII [Hageman] | | Deficiency of factor XIII [fibrin stabilizing] | | Dysfibrinogenemia (congenital) | | Hypoproconvertinemia | | Owren's disease | | Proaccelerin deficiency |
|
|
| |
| D68.3 |
|
Hemorrhagic disorder due to circulating anticoagulants |
| |
| D68.31 |
|
Hemorrhagic disorder due to intrinsic circulating anticoagulants, antibodies, or inhibitors |
| |
| D68.311 |
|
Acquired hemophilia |
| |
| Autoimmune hemophilia | | Autoimmune inhibitors to clotting factors | | Secondary hemophilia |
|
| | |
| D68.312 |
|
Antiphospholipid antibody with hemorrhagic disorder |
| |
| Lupus anticoagulant (LAC) with hemorrhagic disorder | | Systemic lupus erythematosus [SLE] inhibitor with hemorrhagic disorder |
| Excludes1 |
antiphospholipid antibody, finding without diagnosis (R76.0)
lupus anticoagulant (LAC) finding without diagnosis (R76.0)
systemic lupus erythematosus [SLE] inhibitor finding without diagnosis (R76.0)
|
| Excludes2 |
antiphospholipid antibody syndrome (D68.61)
antiphospholipid antibody with hypercoagulable state (D68.61)
lupus anticoagulant (LAC) with hypercoagulable state (D68.62)
systemic lupus erythematosus [SLE] inhibitor with hypercoagulable state (D68.62)
|
|
| | |
| D68.318 |
|
Other hemorrhagic disorder due to intrinsic circulating anticoagulants, antibodies, or inhibitors |
| |
| Antithromboplastinemia | | Antithromboplastinogenemia | | Hemorrhagic disorder due to intrinsic increase in antithrombin | | Hemorrhagic disorder due to intrinsic increase in anti-VIIIa | | Hemorrhagic disorder due to intrinsic increase in anti-IXa | | Hemorrhagic disorder due to intrinsic increase in anti-XIa |
|
| | | |
| D68.32 |
|
Hemorrhagic disorder due to extrinsic circulating anticoagulants |
| |
| Drug-induced hemorrhagic disorder | | Hemorrhagic disorder due to increase in anti-IIa | | Hemorrhagic disorder due to increase in anti-Xa | | Hyperheparinemia |
| UseAdditionalCode |
code for adverse effect, if applicable, to identify drug (T45.515, T45.525)
|
|
| |
| |
| D68.4 |
|
Acquired coagulation factor deficiency |
| |
| Deficiency of coagulation factor due to liver disease | | Deficiency of coagulation factor due to vitamin K deficiency |
| Excludes1 |
vitamin K deficiency of newborn (P53)
|
|
|
| |
| D68.5 |
|
Primary thrombophilia |
| |
| Primary hypercoagulable states |
| Excludes1 |
antiphospholipid syndrome (D68.61)
lupus anticoagulant (D68.62)
secondary activated protein C resistance (D68.69)
secondary antiphospholipid antibody syndrome (D68.69)
secondary lupus anticoagulant with hypercoagulable state (D68.69)
secondary systemic lupus erythematosus [SLE] inhibitor with hypercoagulable state (D68.69)
systemic lupus erythematosus [SLE] inhibitor finding without diagnosis (R76.0)
systemic lupus erythematosus [SLE] inhibitor with hemorrhagic disorder (D68.312)
thrombotic thrombocytopenic purpura (M31.19)
|
|
| |
| D68.51 |
|
Activated protein C resistance |
| |
|
| | |
| D68.52 |
|
Prothrombin gene mutation |
| | |
| D68.59 |
|
Other primary thrombophilia |
| |
| Antithrombin III deficiency | | Hypercoagulable state NOS | | Primary hypercoagulable state NEC | | Primary thrombophilia NEC | | Protein C deficiency | | Protein S deficiency | | Thrombophilia NOS |
|
| |
| |
| D68.6 |
|
Other thrombophilia |
| |
| Other hypercoagulable states |
| Excludes1 |
diffuse or disseminated intravascular coagulation [DIC] (D65)
heparin induced thrombocytopenia (HIT) (D75.82-)
hyperhomocysteinemia (E72.11)
|
|
| |
| D68.61 |
|
Antiphospholipid syndrome |
| |
| Anticardiolipin syndrome | | Antiphospholipid antibody syndrome |
| Excludes1 |
anti-phospholipid antibody, finding without diagnosis (R76.0)
|
| Excludes2 |
anti-phospholipid antibody with hemorrhagic disorder (D68.312)
lupus anticoagulant syndrome (D68.62)
|
|
| | |
| D68.62 |
|
Lupus anticoagulant syndrome |
| |
| Lupus anticoagulant | | Presence of systemic lupus erythematosus [SLE] inhibitor |
| Excludes1 |
lupus anticoagulant (LAC) finding without diagnosis (R76.0)
|
| Excludes2 |
anticardiolipin syndrome (D68.61)
antiphospholipid syndrome (D68.61)
lupus anticoagulant (LAC) with hemorrhagic disorder (D68.312)
|
|
| | |
| D68.69 |
|
Other thrombophilia |
| |
| COVID-19 associated hypercoagulability | | Hypercoagulable states NEC | | Secondary hypercoagulable state NOS |
| CodeAlso |
, if applicable, associated condition
|
|
| |
| |
| D68.8 |
|
Other specified coagulation defects |
| |
| COVID-19 associated coagulopathy |
| CodeAlso |
, if applicable, associated condition
|
| Excludes1 |
hemorrhagic disease of newborn (P53)
|
|
|
| |
| D68.9 |
|
Coagulation defect, unspecified |
|